"I am proud that in 2009 t2cure continued to grow the position of our
stem cell-based therapy in the market and that this product is currently used
for the treatment of patients with acute myocardial infarction in several
major hospitals in
"The efficacy and safety of our lead product t2c001 has only recently been confirmed by the publication of 2-year data from our Phase II-trial in acute myocardial infarction," said Dr. Rueck, Co-CEO of t2cure. "We have recently initiated the certification process for our lead product under the EMEA regulation for Advanced Therapy Medicinal Products. t2cure is one of the first companies worldwide to apply for EMEA certification. Certification will bring us significantly closer to a Centralized European Approval for our lead product, and we expect the certification process to be completed in early 2010."
Before being appointed to CEO, Dr.
About t2cure GmbH
t2cure GmbH is a biopharmaceutical company engaged in the field of stem cell-based regenerative medicine. It develops and markets autologous bone marrow-derived progenitor cells as regenerative therapeutics for cardiovascular disease including ischemic heart disease (acute myocardial infarction and chronic ischemic heart disease), non-ischemic heart failure and peripheral arterial occlusive disease. The most advanced project (t2c001-AMI) has successfully passed Phase II of clinical development.
t2cure is privately financed with EF Investments (Luxembourg) S.a.r.l. as lead investor. Company contact: Dr. Petra Rueck, CEO t2cure GmbH Bettinastrasse 35-37 D-60325 Frankfurt am Main Tel: +49-69-75-61-46-87-0 Fax: +49-69-75-61-46-87-9 Email: firstname.lastname@example.org http://www.t2cure.com Media contact: Frank Butschbacher Investor Relations & Communications http://www.butschbacher.net +43-650-7844940 email@example.com
SOURCE t2cure GmbH